OTCMKTS:ANTH Anthera Pharmaceuticals (ANTH) Stock Price, News & Analysis → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ANTH Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume103 shsMarket Capitalization$1,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsSEC FilingsShort InterestStock AnalysisChartFinancialsSEC FilingsShort Interest Get Anthera Pharmaceuticals alerts: Email Address Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Anthera Pharmaceuticals Stock (OTCMKTS:ANTH)Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.Read More Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> ANTH Stock News HeadlinesJune 28, 2023 | finance.yahoo.comMACK - Merrimack Pharmaceuticals, Inc.May 16, 2023 | marketwatch.comIndustry Research Report on Cystic Fibrosis Drugs Market Share and Industrial Overview till 2030April 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.May 16, 2023 | marketwatch.comSystemic Lupus Erythematosus (SLE) Drugs Market Updates: 2023-2030 ForecastMay 5, 2023 | marketwatch.com2023-2030 Vasculitis Treatment Market Size (Growth and Outlook) includes Main Business Overview | with [124 Pages]May 4, 2023 | marketwatch.com2023-2030 Gaucher Disease Treatment Market Size (Growth and Outlook) includes Company Information | with [104 Pages]April 28, 2023 | marketwatch.comGaucher Disease Treatment Market Top Key Players by 2030April 7, 2023 | marketwatch.comGlobal Cystic Fibrosis Drugs Market Size 2023 to 2026 Size and Share Survey ReportApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.March 28, 2023 | marketwatch.comCeliac Disease Drug Market Size and Forecast till 2030March 10, 2023 | marketwatch.comCystic Fibrosis Drugs Market 2023-2028 Recent Study by Trend and Growth AnalysisMarch 8, 2023 | finance.yahoo.comInfectious disease specialist Dr. Regis A. Vilchez is appointed CMO of MicuRx Pharmaceuticals, Inc.February 26, 2023 | thestreet.comTwo Drugs, Designed To Help Patients, Actually Hurt ThemJanuary 13, 2023 | marketwatch.comGaucher Disease Treatment Market Provides an In-Depth Insight of Trends and Landscape Outlook 2023-2028January 7, 2023 | marketwatch.comCeliac Drugs Market Trends, Business Overview, Industry Growth, and Forecast 2023 To 2028December 17, 2022 | marketwatch.comGaucher Disease Treatment Market Research report forecast 2023 To 2028, Latest Industry News, Top Company Analysis, Research MethodologyOctober 12, 2022 | marketwatch.comCystic Fibrosis Drugs Market 2022 | Upcoming Trends, Recent Development, Top Manufacturers, Industry Drivers and Forecast to 2028September 1, 2022 | apnews.comThryv Therapeutics Inc. Announces the Appointment of Dr. Debra Odink to President and Dr. Shi Yin Foo to the Board of DirectorsAugust 26, 2022 | reuters.comANTH.PQ - Anthera Pharmaceuticals Inc | Stock Price & Latest News | ReutersJune 10, 2022 | benzinga.comAnthera Pharmaceuticals (OTC:ANTH), Short Interest ReportMay 10, 2022 | marketwatch.comVasculitis Treatment Market Size 2022 including Scope, Trends, Manufacturers, Growth Factors, Market Dynamics and Forecast to 2028April 21, 2022 | bizjournals.comThe Petri Dish: Two startups get new CEOs, workforce dev coalition ramps upApril 14, 2022 | finanznachrichten.deNervGen Pharma Corp.: NervGen Pharma Appoints Craig Thompson to the Board of DirectorsApril 13, 2022 | finance.yahoo.comNervGen Pharma Appoints Craig Thompson to the Board of DirectorsNovember 24, 2021 | finanznachrichten.deSanthera Pharmaceuticals Holding AG: Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD StudyOctober 26, 2021 | sg.finance.yahoo.comAnthera Pharmaceuticals, Inc. (ANTH)October 4, 2021 | marketwatch.comEPI Market 2021 : Global Industry Analysis, Trends, Market Size and Forecasts Up to 2025 with Dominant Sectors and Countries DataSee More Headlines Receive ANTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anthera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/05/2018Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:ANTH CUSIPN/A CIK1316175 Webwww.anthera.com Phone(410) 350-1839Fax510-856-5597Employees21Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares5,750,000Free FloatN/AMarket Cap$1,000.00 OptionableNot Optionable Beta1.91 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Paul F. Truex M.B.A. (Age 55)Executive Chairman Comp: $100kMr. John Craig Thompson (Age 57)CEO & Director Comp: $715.3kMs. May Liu (Age 48)Senior VP of Finance & Administration and Principal Accounting Officer Comp: $373.44kDr. Paul Adams Ph.D. (Age 61)Senior Vice President of Global Regulatory Affairs and Compliance Joshua CaldwellChief Liquidating OfficerKey CompetitorsAbliva AB (publ)OTCMKTS:NEVPFAcusphereOTCMKTS:ACUSAddex TherapeuticsOTCMKTS:ADDXFAeolus PharmaceuticalsOTCMKTS:AOLSAffymaxOTCMKTS:AFFYView All Competitors ANTH Stock Analysis - Frequently Asked Questions How were Anthera Pharmaceuticals' earnings last quarter? Anthera Pharmaceuticals, Inc. (OTCMKTS:ANTH) issued its earnings results on Monday, March, 5th. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.82) by $0.09. When did Anthera Pharmaceuticals' stock split? Anthera Pharmaceuticals's stock reverse split on Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Anthera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anthera Pharmaceuticals investors own include Ocular Therapeutix (OCUL), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Arena Pharmaceuticals (ARNA), OPKO Health (OPK), AVEO Pharmaceuticals (AVEO), Amicus Therapeutics (FOLD) and Alibaba Group (BABA). How do I buy shares of Anthera Pharmaceuticals? Shares of ANTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ANTH) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anthera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
